Intended for healthcare professionals

Feature Investigation

Rivaroxaban: can we trust the evidence?

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i575 (Published 03 February 2016) Cite this as: BMJ 2016;352:i575

Updates on the validity of ROCKET-AF conclusion based on issues with point-of-care INR results: Defence or Defiance?

Dear Editors

I believe that interested readers would like to be informed on the recent published letter from Dr JR Powell regarding his concerns with point-of-care INR readings used in the ROCKET-AF and the study author's response:

http://www.nejm.org/doi/full/10.1056/NEJMc1604020?query=TOC

However I do not believe NEJM has published any letters from Thomas Marcinicak mentioned in this BMJ article. No free access to datasets has been offered as far as I can tell.

For some, the veil of secrecy that remains even when significant allegations of the study validity has been openly voice, will only result in a slow erosion of confidence from lingering doubts

Competing interests: No competing interests

28 July 2016
Shyan Goh
Orthopaedic Surgeon
Sydney, Australia